Link :- https://interestingengineering.com/science/finger-prick-test…tent=Nov07
Megaflopp/iStock.
The significance of such a test lies in its non-invasive nature and the potential to detect brain tumors at an earlier stage, which can be critical for timely treatment and improved patient outcomes.
Germany: A recent study published in the International Forum of Allergy & Rhinology has shown the effectiveness of the probiotic treatment with Enterococcus faecalis in reducing the symptoms of allergic rhinitis after four weeks.
The results are in line with similar studies showing the beneficial effects of E. faecalis. Furthermore, the data showed that allergic symptoms were alleviated during the COVID-19 pandemic situation. This is in line with previous studies and might be explained by a reduced confrontation with pollen due to masks, psychological factors, or lockdown situations.
Although allergic rhinitis treatment has been proven to be effective, it is expensive, does not completely resolve symptoms, and is related to side effects. Previous studies have indicated that probiotics may be a new promising treatment for allergic rhinitis. Michael Schaefer, Medical School Berlin, Berlin, Germany, and colleagues aimed to evaluate the effects of a single bacterial strain, Enterococcus faecalis on symptoms of allergic rhinitis. Beneficial effects of E. faecalis have been reported before but not in seasonal allergic rhinitis.
The interaction was captured using a specialized piece of kit called a transmission electron microscope.
Researchers at the University of Chicago’s Pritzker School of Molecular Engineering, led by Giulia Galli, have conducted a computational study predicting the conditions necessary to create specific spin defects in silicon carbide. These findings, detailed in a paper published in Nature Communications
<em> Nature Communications </em> is a peer-reviewed, open-access, multidisciplinary, scientific journal published by Nature Portfolio. It covers the natural sciences, including physics, biology, chemistry, medicine, and earth sciences. It began publishing in 2010 and has editorial offices in London, Berlin, New York City, and Shanghai.
…Such moves are helping countries like the United Kingdom to develop the expertise needed to guide AI for the public good, says Bengio. But legislation will also be needed, he says, to safeguard against the development of future AI systems that are smart and hard to control.
We are on a trajectory to build systems that are extremely useful and potentially dangerous, he says. We already ask pharma to spend a huge chunk of their money to prove that their drugs aren’t toxic. We should do the same.
Researchers have uncovered that proteins use a common chemical label as a shield to protect them from degradation, which in turn affects motility and aging. Proteins are key to all processes in our cells and understanding their functions and regulation is of major importance.
“For many years, we have known that nearly all human proteins are modified by a specific chemical group, but its functional impact has remained undefined,” says professor Thomas Arnesen at the Department of Biomedicine, University of Bergen.
Scientists from the University of California Davis (UC Davis) Comprehensive Cancer Center have recently published in Cell Death and Disease, identifying a critical protein that causes cells to die. The protein is described as an epitope, which is a section of the protein that is recognized by the immune system to activate a response. This epitope was distinctly found on the CD95 receptor, known to trigger programmed cell death. The report demonstrates a new mechanism to trigger cell death and provide further insight into improved disease treatments.
CD95 receptors, also referred to a “Fas”, are cell death receptors which are present on cell membranes. Once Fas is activated, it generates a signaling cascade which elicits cell death. The mechanism by which cells self-destruct has been an important research topic. By understanding cell death, scientists can generate better therapies for different diseases, including cancer.
Currently, cancer is treated by surgery, chemotherapy, or radiotherapy. Despite initial success, these treatments are unable to fully eradicate tumor cells. Immunotherapy is a new approach to target cancer. Immunotherapy refers to therapeutics modulating the immune system to elicit an effective immune response. This is a more indirect approach compared to lysing tumors with a chemical. One specific immunotherapy referred to as chimeric antigen receptor (CAR) T-cell therapy is a treatment in which T cells, or cytotoxic immune cells, are engineered to lyse tumor cells. Unfortunately, CAR T-cell therapy is limited due to the tumor’s ability to prevent T cell activation.
Two people born on the same day can age very differently.
Biological age diagnostics help pinpoint the rate a person ages regardless of the amount of time they have spent on earth. This could provide earlier detection of disease for personalised preventative strategies.
Our FREE comprehensive market intelligence report demonstrates how biological age diagnostics are radically transforming how we see and tackle aging.
After enduring intense treatments and a 10-hour surgery as a high school junior to treat a rare form of cancer, Callan currently has no evidence of disease and is a student of fine arts at the University of Texas. Read how his family is helping others diagnosed with this rare cancer.
In October 2021, Callan began experiencing a mysterious pain in his neck. A talented artist and a good student, Callan had been looking forward to his junior year of high school. After also developing a cough, he was diagnosed with walking pneumonia, but later imaging showed a large tumor in his chest.
Multiple doctors told Callan the tumor, diagnosed as synovial sarcoma, was inoperable. Synovial sarcoma is often deadly without surgery, but his family eventually found a team willing to operate. Callan currently has no evidence of disease.
Bendamustine administration within 9 months of apheresis significantly reduced response rates and survival in patients with relapsed/refractory large B-cell lymphoma:
CD19-directed chimeric antigen receptor (CAR) T-cell therapy provides durable responses and a potential cure in approximately one third of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Although it is known that therapy with the lymphotoxic chemotherapy agent bendamustine, prior to autologous T-cell collection, can impair T-cell number and function, its impact on patient outcomes has not been systematically addressed.
Investigators have now conducted a retrospective, multicenter study of 439 patients with R/R LBCL who had received two or more previous lines of therapy and were infused with commercially available CD19-targeted CAR T cells (axicabtagene ciloleucel or tisagenlecleucel). Of these patients, 80 (18%) had received one or more cycles of bendamustine, including 42 who had been treated within 9 months of apheresis. At baseline, bendamustine-exposed patients, compared with bendamustine-naive patients, were older (66 vs. 61 years), had poorer performance status (1, 16% vs. 7%), were more heavily pretreated (2 previous lines of therapy, 71% vs. 28%), and were more likely to have transformed indolent B-cell lymphoma (45% vs. 15%).
At apheresis, bendamustine-exposed patients, compared with bendamustine-naive patients, had a significantly poorer overall response rate (ORR; 53% vs. 72%; P0.01), shorter progression-free survival (PFS; 3.1 vs. 6.2 months; P0.04), and shorter overall survival (OS; 10.3 vs. 23.5 months; P0.01). For those who received bendamustine within 9 months of apheresis, ORR was even lower (40%), and PFS and OS were shorter (1.3 and 4.6 months, respectively). Bendamustine-exposed patients also had lower absolute lymphocyte counts, lower CD4+ T-cell counts, and poorer CAR T-cell expansion, but had similar rates of cytokine release syndrome and immune-effector cell-associated neurotoxicity syndrome.
Continue reading “Bendamustine Impairs Outcomes with CAR T-Cell Therapy” »
